Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
98 hedge funds and large institutions have $641M invested in Aerie Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 12 closing their positions.
183% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 12
56% more capital invested
Capital invested by funds: $410M → $641M (+$231M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
29% more funds holding
Funds holding: 76 → 98 (+22)
12% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$54.2M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$17M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$10.6M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$8.23M |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$7.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$33M |
| 2 |
DM
Deerfield Management
New York
|
-$11.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.4M |
| 4 |
Goldman Sachs
New York
|
-$5.63M |
| 5 |
PA
Perceptive Advisors
New York
|
-$5.44M |
AERI Hedge Fund Activity: Q4 2014 in Review
98 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q4 2014, worth a combined $641M — up 56% from $410M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new AERI positions and 12 closed out — a net gain of 22 holders — while 28 added to existing stakes and 25 trimmed.
The largest buyer was Jennison Associates, adding an estimated $54.2M. The largest seller was TPG Group Holdings (SBS) Advisors, cutting an estimated $33M.
- 98 institutional investors held Aerie Pharmaceuticals (AERI) as of Q4 2014, up from 76 in Q3 2014.
- Funds reported $641M of Aerie Pharmaceuticals stock for Q4 2014, up 56% quarter-over-quarter.
- 34 funds opened new Aerie Pharmaceuticals positions in Q4 2014 and 12 closed out, a net change of +22 holders.
- The largest Aerie Pharmaceuticals buyer in Q4 2014 was Jennison Associates, an estimated $54.2M added.
- The largest Aerie Pharmaceuticals seller in Q4 2014 was TPG Group Holdings (SBS) Advisors, an estimated $33M sold.
Based on aggregated 13F filings for Q4 2014.